CERo Therapeutics Holdings, Inc.
CEROW·NasdaqGM
0.0041+0.0004 (+10.81%)today
At close: Oct 14, 4:00 PM EDT · May be delayed up to 15 min · USD
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Previous close0.0037
Open0.0018
Day range0.00180.0041
52-week range—
Off day high0.00%
Off 52-week high0.00%
Volume2.00K
Avg. volume (3M)—
Market cap—
EPS (TTM)—
Forward P/E—
P/E ratio (TTM)—
Dividend yield—
Beta (5Y)0.22
Shares outstanding—
Short interest—
Earnings date—
Analyst target—
Profit margin0.00%
Against its peers
Compare in full ›| CEROW | ETRA | CVM | ATRA | KAPA | COR | |
|---|---|---|---|---|---|---|
| Market cap | — | 578.40M | 27.79M | 94.25M | 1.90M | 64.61B |
| P/E (TTM) | — | — | — | — | — | 25.1 |
| Forward P/E | — | -5.1 | -0.2 | 6.1 | -0.1 | 17.1 |
| Price/book | 0.0 | 0.0 | 2.5 | -2.4 | 0.4 | 21.2 |
| Dividend yield | — | — | — | — | — | 0.71% |
| 1-year change | — | −31.70% | −81.98% | −33.78% | −92.44% | +3.61% |
| Today | +10.81% | +1.82% | −2.47% | +0.43% | −2.72% | −0.54% |
The closest companies by business. Prices may be delayed up to 15 min.
Latest news
All CEROW news ›SRX Global and CERO 1236, a Wholly-Owned SPV, Enter into Definitive Agreement to Acquire CERo Therapeutics, an Innovative Cellular Immunotherapy Company Developing CER 1236 for Hematologic Malignancies
SRX expects capital to be raised directly into the subsidiary without diluting existing SRX Global shareholders. SRX disclosed a senior secured debt investment in CERo, the same company now covered by the acquisition agreement. 24h Move is…
From articles in the 4Search news index.
In the news
1mentions in 30 days
1with it in the headline
Positivesentiment
Mentioned with
People in the coverage
Most coverage from
-
stocktitan.net1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 1 articles, not a forecast.